Anti-Seizure Drug Pharmacology

Correct Answer

C — Hydantoin

Rationale

Phenytoin is a hydantoin — the founding member of this drug class and one of the oldest anti-seizure drugs in clinical use. Barbiturates include phenobarbital and primidone. Succinimides include ethosuximide, the first-line agent for childhood absence epilepsy. Benzodiazepines include diazepam, lorazepam, and clonazepam. Knowing the parent class for each major anti-seizure drug is the foundation for understanding their shared properties and distinguishing features.

Correct Answer

A — A water-soluble prodrug of phenytoin used for intravenous administration

Rationale

Fosphenytoin is a water-soluble prodrug that is rapidly converted to phenytoin after intravenous administration. It was developed to address the cardiovascular risks of intravenous phenytoin, which requires a propylene glycol vehicle that contributes to cardiac arrhythmia and hypotension. Fosphenytoin lacks this vehicle and can be infused more rapidly and with less cardiovascular risk. It is not an independent drug with its own mechanism — once converted to phenytoin, it acts identically to orally administered phenytoin. Options B, C, and D describe relationships to phenytoin that fosphenytoin does not have.

Correct Answer

D — Carbamazepine

Rationale

Carbamazepine is the drug of choice for trigeminal neuralgia — a severe facial pain syndrome caused by aberrant high-frequency firing in the trigeminal nerve. This non-epilepsy indication is a high-yield classification fact. The same sodium channel blocking mechanism that suppresses seizure activity also suppresses the ectopic neuronal discharge responsible for trigeminal neuralgia pain. Phenytoin, lamotrigine, and oxcarbazepine are sodium channel blockers used for seizures but are not the established first-line agents for trigeminal neuralgia.

Correct Answer

B — Oxcarbazepine is a structural analog of carbamazepine with a lower risk of hematologic adverse effects

Rationale

Oxcarbazepine is a structural analog of carbamazepine that shares the same sodium channel blocking mechanism and similar clinical indications. Its principal advantage over carbamazepine is a lower risk of aplastic anemia and agranulocytosis, as well as no autoinduction and fewer drug interactions. Its principal disadvantage is a higher rate of hyponatremia. Oxcarbazepine is not a prodrug of carbamazepine — it is a distinct compound that is itself metabolized to an active monohydroxy derivative. It has the same mechanism category as carbamazepine, not a different one.

Correct Answer

C — Lamotrigine

Rationale

Lamotrigine is the only sodium channel blocker in this group classified as broad-spectrum. Unlike phenytoin, carbamazepine, and oxcarbazepine — which are effective for focal and tonic-clonic seizures but can worsen absence seizures — lamotrigine retains efficacy against absence seizures and is used in juvenile myoclonic epilepsy and other mixed generalized epilepsy syndromes. This broader spectrum makes lamotrigine a preferred option when a sodium channel blocker is needed for a patient with multiple seizure types.

Correct Answer

A — Cytochrome P450 enzyme inducer

Rationale

Phenytoin is a potent inducer of hepatic cytochrome P450 enzymes, particularly cytochrome P450 3A4 and cytochrome P450 2C9. This induction accelerates the metabolism of many co-administered drugs, reducing their plasma levels and clinical effect. Clinically important examples include warfarin, oral contraceptives, and other anti-seizure drugs. Carbamazepine shares this enzyme-inducing property. Lamotrigine, by contrast, is metabolized by glucuronidation and is not a cytochrome P450 inducer. Valproate is a cytochrome P450 inhibitor, not an inducer — a distinction that creates the clinically important valproate-lamotrigine interaction.

Correct Answer

B — Phenytoin exhibits zero-order kinetics at therapeutic concentrations, so a small dose increase produces a disproportionately large rise in plasma level

Rationale

Phenytoin undergoes zero-order (saturation) kinetics at therapeutic doses. The hepatic enzymes responsible for phenytoin metabolism become saturated within the therapeutic range — once this occurs, the elimination rate becomes fixed regardless of concentration, and any further increase in dose accumulates disproportionately in the plasma. A modest 17 percent dose increase here doubled the plasma level. This is why phenytoin has a notoriously narrow therapeutic window and requires plasma level monitoring. Nystagmus and ataxia are the characteristic cerebellar signs of phenytoin toxicity at supratherapeutic concentrations. Option A describes autoinhibition, which phenytoin does not produce. Option C describes carbamazepine autoinduction, not phenytoin behavior.

Correct Answer

D — Phenytoin

Rationale

Gingival hyperplasia — overgrowth of gum tissue — is the most distinctive chronic adverse effect of phenytoin and is not produced by other anti-seizure drugs. It occurs in up to 50 percent of patients on long-term phenytoin therapy. The combination of gingival hyperplasia, hirsutism (increased body hair), and coarsening of facial features is characteristic of chronic phenytoin exposure and constitutes a recognizable clinical triad. Carbamazepine produces hyponatremia and carries hematologic risks but does not cause gingival hyperplasia. Lamotrigine's signature adverse effect is Stevens-Johnson syndrome with rapid titration. Levetiracetam is associated with behavioral effects such as irritability and aggression, not the cosmetic changes described here.

Correct Answer

A — Fosphenytoin lacks the propylene glycol vehicle responsible for the cardiac arrhythmia and hypotension associated with intravenous phenytoin

Rationale

Intravenous phenytoin is dissolved in a propylene glycol vehicle that contributes to cardiac arrhythmia and hypotension when infused — it must be given slowly with continuous cardiac monitoring. Fosphenytoin is water-soluble and does not require this vehicle, allowing faster infusion with substantially less cardiovascular risk. Once administered, fosphenytoin is rapidly converted to phenytoin by plasma phosphatases, so it produces identical anti-seizure effects. Option B reverses the pharmacokinetic reality — fosphenytoin requires conversion before it is active. Options C and D describe properties that fosphenytoin does not possess.

Correct Answer

C — Carbamazepine induces its own metabolism through cytochrome P450 3A4, shortening its half-life and reducing plasma levels over the first weeks of therapy

Rationale

Carbamazepine is an autoinducer — it induces its own metabolism through cytochrome P450 3A4. At the start of therapy, carbamazepine has a half-life of approximately 36 hours. Over the first several weeks, autoinduction progressively shortens this to 12 to 17 hours, causing plasma levels to fall even with a fixed dose. Dose adjustment is often required during the first month of treatment to maintain therapeutic levels. This is a property unique to carbamazepine among the sodium channel blockers — phenytoin, lamotrigine, and oxcarbazepine do not autoinduct. Zero-order kinetics is a property of phenytoin, not carbamazepine.

Correct Answer

B — HLA-B*1502 — to identify patients at markedly elevated risk for Stevens-Johnson syndrome with carbamazepine

Rationale

The HLA-B*1502 allele is strongly associated with carbamazepine-induced Stevens-Johnson syndrome — a severe, potentially fatal hypersensitivity reaction involving epidermal detachment. This allele is found predominantly in patients of East Asian descent, including Han Chinese, Thai, and other Southeast Asian populations. Genetic screening for HLA-B*1502 before initiating carbamazepine is recommended in patients from these populations. HLA-B*5701 is associated with abacavir hypersensitivity, not lamotrigine reactions. The cytochrome P450 variants in options A and D, while pharmacogenomically relevant, are not the standard pre-treatment screen for carbamazepine in this clinical context.

Correct Answer

D — A lower starting dose is required because valproate inhibits lamotrigine glucuronidation, approximately doubling lamotrigine plasma levels

Rationale

Lamotrigine is metabolized primarily by hepatic glucuronidation. Valproate is a potent inhibitor of this pathway and raises lamotrigine plasma levels approximately two-fold. When lamotrigine is added to a regimen that already includes valproate, the starting dose must be halved and the titration must proceed more slowly than usual. Failure to make this adjustment substantially increases the risk of Stevens-Johnson syndrome, which is already a concern with rapid lamotrigine titration. This interaction is one of the most clinically important drug interactions in anti-seizure pharmacology. Option A has the direction of the interaction reversed — valproate inhibits, not induces, lamotrigine metabolism.

Correct Answer

A — Rapid titration produces high peak plasma levels that overwhelm glucuronidation capacity, increasing Stevens-Johnson syndrome risk

Rationale

Lamotrigine carries a significant risk of Stevens-Johnson syndrome — a severe, potentially life-threatening reaction involving widespread epidermal detachment. This risk is strongly associated with rapid dose escalation, which produces high plasma concentrations before the body can accommodate the drug. The prescribing requirement for slow titration — low starting dose with increases over weeks, not days — is a safety mandate, not a preference. Any rash that develops during lamotrigine titration must be evaluated urgently. The concurrent use of valproate, which raises lamotrigine levels by inhibiting its glucuronidation, further increases this risk. Options B, C, and D describe mechanisms that lamotrigine does not produce.

Correct Answer

C — Carbamazepine induces cytochrome P450 enzymes that accelerate metabolism of oral contraceptive hormones, reducing their plasma levels and contraceptive efficacy

Rationale

Carbamazepine is a potent inducer of hepatic cytochrome P450 enzymes, particularly cytochrome P450 3A4. These enzymes metabolize estrogen and progestin components of oral contraceptives, and induction accelerates this metabolism, reducing hormone plasma levels and contraceptive efficacy. This interaction can result in unintended pregnancy. Phenytoin shares this enzyme-inducing property and carries the same interaction risk. Patients on either drug who require contraception should be counseled to use additional or alternative contraceptive methods. Lamotrigine is not a cytochrome P450 inducer and does not carry this interaction risk, making it a preferable option when contraceptive reliability is a concern.

Correct Answer

B — Phenytoin

Rationale

The triad of cleft palate, hypoplastic distal phalanges, and intrauterine growth restriction is the defining pattern of fetal hydantoin syndrome — the teratogenic presentation of in-utero phenytoin exposure. This syndrome is a recognized and named teratogenic outcome associated specifically with phenytoin and is high-yield for examinations. Lamotrigine has a more favorable teratogenic profile than phenytoin and is not associated with this pattern of abnormalities; it is a preferred agent when anti-seizure treatment during pregnancy is necessary. Levetiracetam also has a favorable pregnancy safety profile. Oxcarbazepine carries teratogenic risk but is not associated with the fetal hydantoin syndrome pattern.

Correct Answer

D — Carbamazepine produces a syndrome of inappropriate antidiuretic hormone secretion-like effect, causing water retention and dilutional hyponatremia

Rationale

Carbamazepine causes hyponatremia through a syndrome of inappropriate antidiuretic hormone secretion-like mechanism — it enhances the action of antidiuretic hormone on the renal collecting duct, promoting water reabsorption and diluting serum sodium. The resulting hyponatremia is dilutional rather than caused by sodium loss. This adverse effect is particularly relevant in elderly patients, who have reduced capacity to excrete free water and are more susceptible to the neurological consequences of hyponatremia. Oxcarbazepine produces this effect at an even higher rate than carbamazepine. Options A, B, and C describe renal mechanisms that carbamazepine does not produce.

Correct Answer

A — Lamotrigine has a more favorable teratogenic risk profile than valproate, which carries the highest teratogenic risk among anti-seizure drugs

Rationale

Valproate carries the highest teratogenic risk of any anti-seizure drug — it is associated with neural tube defects, craniofacial abnormalities, and neurodevelopmental impairment at rates far above background. Lamotrigine has a substantially more favorable teratogenic profile and is a preferred option when anti-seizure treatment during pregnancy cannot be avoided. While valproate remains first-line for juvenile myoclonic epilepsy in general, its teratogenic risk makes it a poor choice for women of childbearing potential who may become pregnant. Levetiracetam is another alternative with a favorable pregnancy profile. Option B overstates the efficacy difference — valproate is the more established first-line agent for juvenile myoclonic epilepsy. Options C and D describe properties that lamotrigine does not possess.

Correct Answer

C — Oxcarbazepine carries a substantially lower risk of aplastic anemia and agranulocytosis than carbamazepine

Rationale

Carbamazepine carries a risk of aplastic anemia and agranulocytosis — rare but potentially fatal hematologic adverse effects that require complete blood count monitoring. In a patient with a history of drug-induced agranulocytosis, this risk profile makes carbamazepine a poor choice. Oxcarbazepine is a structural analog with the same sodium channel mechanism and similar anti-seizure efficacy, but with a substantially lower rate of these hematologic complications. This is its principal advantage over carbamazepine. Option A is partially true — oxcarbazepine does have fewer cytochrome P450 interactions — but it does not explain the hematologic risk reduction. Option D overstates the safety of oxcarbazepine; hematologic monitoring remains prudent, though the risk is lower.